Clinical evaluation of defibrotide in the treatment of arterial and venous vascular disease. A preliminary report.

Defibrotide is a new compound with antithrombotic and profibrinolytic activity. It increases the endogenous fibrinolytic activity by promoting the cellular activator of plasminogen from endothelial cells and by decreasing the concentration of its inhibitors. In this study we evaluated a total of 223 patients for a mean period of 43 days for the following vascular conditions: (a) superficial venous thrombosis; (b) prophylaxis against deep venous thrombosis; (c) peripheral vascular disease (ischaemic foot and intermittent claudication; (d) prophylaxis against TIAs in patients with carotid plaques determining embolization; (e) treatment of venous ulcerations determined by chronic venous incompetence; (f) patients with Raynaud's phenomenon and disease.

[Environment microbiological control in a department with patients at great risk (author's transl)].

Microbic flora has been studied in the Centro di Rianimazione of the Ospedali Riuniti in Chieti to control validity of the antibacterial systems and to verify efficacy of the filter systems that allow the admission into the isolation boxes, stopping great bacterial exogenous increases. These inspection have been executed by suction system Batteriological Air Pollution Detector.

[Observations on antibiotic sensitivity of "Pseudomonas aeruginosa" strains isolated in pediatric wards (author's transl)].

It has been studied the antibiotic sensitivity of 27 Pseudomonas aeruginosa strains belonging to only two types, isolated hospitalized children and responsible of different clinical pictures. The strains were in vitro resistant to Carbenicillin, Sisomicine, Gentamycine and many other antibiotic tested, partially resistant to Tobramycin and sensitive to Amikacine, Polimixine B and Colistatin.